Here are Top health stories of the day
Coronavirus Omicron variant India : 1,114 new cases in Delhi, 447 in Mumbai
OmiSure RT-PCR test detects sub-lineages of Omicron : Tata Medical and Diagnostics
Tata Medical and Diagnostics on Tuesday said its OmiSure RT-PCR(Reverse Transcriptase Polymerase Chain Reaction) test has been upgraded to detect the new BA.2 sub-lineages of Omicron. In an evaluation carried out by ICMR and the Virus Research & Diagnostics Laboratory, Kasturba Hospital for Infectious Diseases, Mumbai, the upgraded OmiSure successfully detected BA.1, BA.1.1, and BA.2 sub-lineages of Omicron, the company said in a statement.
With this, the OmiSure RT-PCR test kit is now capable of detecting all the sub-lineages of Omicron prolific in India at present, it added.
For more information, check out the full story on the link below:
OmiSure RT-PCR test detects sub-lineages of Omicron : Tata Medical And Diagnostics
11,629 MD, MS, PG Diploma, DNB seats up for grabs in MCC NEET PG counselling round 2, check out seat matrix
There are a total of 11,629 MD, MS, PG Diploma and DNB seats available for NEET PG Counselling candidates participating in the Round 2 session being conducted by the Medical Counselling Committee, MCC under DGHS.
The confirmation of this aggregate comes from the recently released Round 2 seat matrix on the official website of the Medical Counselling Committee (MCC) indicating the number of MD, MS DNB and PG Diploma seats being offered for the second round of NEET PG Counselling as per the categories available in medical institutes across the country.
For more information, check out the full story on the link below:
COVID-19: Glenmark Launches FabiSpray In India
Drug maker Glenmark Pharmaceuticals Limited and Canadian pharmaceutical company SaNOtize Research & Development Corp. today announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India; for the treatment of adult patients with COVID-19 who have high risk of progression of the disease.
Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.
For more information, check out the full story on the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.